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Background. The CC-chemokines CCL3, CCL4 and CCL5 have been found to block the entry of CCR5-tropic HIV into host cells
and to suppress the viral replication in vitro, but the in vivo role of endogenous CC-chemokines in HIV-1 infection is still
incompletely understood. Methodology/Principle Findings. In this study, the primate host CCL3, CCL4 and CCL5 gene
expression was evaluated in response to simian-human immunodeficiency virus (SHIV) infection in rhesus macaque model.
Five rhesus macaques were inoculated with CCR5-tropic SHIVSF162P4. The mRNA levels of CCL3, CCL4 and CCL5 were measured
by real-time PCR at post inoculation day (PID) 0, 7, 14, 21, 35, 56 and 180 in peripheral blood. In addition, a selected subset of
samples from CXCR4-tropic SHIVKu1-infected macaques was included with objective to compare the differences in CC-
chemokine down-regulation caused by the two SHIVs. Gut-associated lymphoid tissues (GALT) collected from SHIVSF162P4-
infected animals were also tested by flow cytometry and confocal microscopy to corroborate the gene expression results.
Predictably, higher viral loads and CD4+ T cell losses were observed at PID 14 in macaques infected with SHIVKu1 than with
SHIVSF162P4. A decline in CC-chemokine gene expression was also found during primary (PID 7-21), but not chronic (PID 180)
stage of infection. Conclusions. It was determined that A) SHIVSF162P4 down-regulated the CC-chemokine gene expression
during acute stage of infection to a greater extent (p,0.05) than SHIVKu1, and B) such down-regulation was not paralleled with
the CD4+ T cell depletion. Evaluation of CC-chemokine enhancing immunomodulators such as synthetic CpG-oligonucleotides
could be explored in future HIV vaccine studies.
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INTRODUCTION
Chemokines play a critical role in the host defense against viruses
by mobilizing leukocytes to sites of infection, and they also play
a homeostatic role in secondary lymphoid tissues [1]. Structurally,
chemokines are divided into the C, CC, CXC, and CX3C
subclasses on the basis of their N-terminal cysteine residues
spacing [2]. The majority of known chemokines belong to CC or
CXC category [2]. Since CC chemokine receptor 5 (CCR5) and
CXC chemokine receptor 4 (CXCR4) were identified as major co-
receptors for HIV-1 entry into target cells, it was suggested that
these chemokine receptors and their ligands are involved in the
transmission and replication of HIV-1 [3,4]. HIV-1 isolates that
use CCR5 as co-receptor (R5 viruses) are predominantly trans-
mitted and persist throughout the infection. By contrast, HIV-1
isolates that use CXCR4 (X4 viruses) commonly emerge in
infected individuals at later stages of infection [3]. The importance
of CCR5 for HIV-1 transmission was underscored by observation
that certain individuals who had been repeatedly exposed to HIV-
1 but remained uninfected had a defect in CCR5 expression [5]. It
has been documented that mucosa-associated CD4+ T cells,
macrophages, and dendritic cells express CCR5 which makes
them prime targets for the virus [6–8].
Members of the CC-chemokine family, such as macrophage
inflammatory protein (MIP)-1a (CCL3), MIP-1b (CCL4) and
RANTES (CCL5) are the natural ligands for CCR5. They have
been shown to inhibit HIV-1 entry into host cells in vitro by
competing with viral Env protein for binding [9–11], and by
down-regulating CCR5 surface expression [12]. However, the in
vivo role of endogenous CC-chemokines in the pathogenesis of
HIV-1 infection is still incompletely understood. A number of
studies have analyzed levels of CCR5 ligands in the HIV-1/SIV-
infected individuals or monkeys with conflicting results [13–18].
Some of these studies concluded that CCR5 ligands may exert
protective role in HIV-1/SIV infection [13,16–18], while others
suggested an association between elevated levels of CCR5 ligands
and HIV disease progression [14,15]. Most of these reports were
based on data that correspond to chronic stages of HIV-1/SIV
infection, while the relationship between host CC-chemokine
expression and HIV-1 acute infection still needs to be studied.
In this study, we evaluated the host in vivo CCL3, CCL4 and
CCL5 gene expression in response to CCR5-tropic SHIV
infection. We utilized SHIVSF162P4/rhesus macaque model and
focused predominantly on acute stage of infection to measure the
CC-chemokine gene expression changes in peripheral blood and
GALT. In addition, we included a selected subset of samples from
SHIVKu1-infected macaques in order to compare the differences
between the extent of CC-chemokine down-regulation caused by
CCR5-tropic SHIVSF162P4 and more pathogenic CXCR4-tropic
SHIVKu1 at the acute stage of infection.
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Viral loads and CD4+ T cell counts in peripheral
blood of SHIVSF162P4-infected macaques
All five SHIVSF162P4-inoculated macaques became infected as
determined by individual viral load measurements. Highest viral
loads were detected at PID 14 with an average of ,10
5 of viral
copies (Fig. 1A). The lowest average peripheral CD4+ T cell
counts were detected between PID 14 and 21 (Fig. 1B).
Down-regulation of CC-chemokine gene expression
in peripheral blood of SHIVSF162P4-infected macaques
The changes of CCL3, CCL4 and CCL5 gene expression levels
were studied in peripheral blood over the period of half year
following the SHIVSF162P4 inoculation. Decreased expression of all
three CC-chemokines was found upon infection. The lowest gene
expression was detected at PID 14, coinciding with the peak of
primary SHIVSF162P4 infection (Fig. 1A, C, D and E). By PID 14,
CCL3, CCL4 and CCL5 mRNA levels decreased 5.9–13.6, 3.5–
27.5, and 2.3–5.4-folds, respectively. These levels were signifi-
cantly lower (p,0.005 for CCL3; p,0.05 for CCL4 and CCL5)
than those prior to infection (Fig. 1C, D and E). However, such
a decline of CC-chemokine gene expression occurred only
temporarily, because starting from PID 21 and at later time
points these gene expression values showed relative increase. By
PID 180, expressions of all three chemokine genes were no longer
significantly different from those prior to infection.
Down-regulation of CC-chemokine gene expression
in GALT of SHIVSF162P4-infected macaques
To determine whether the decline of CC-chemokine gene
expression occurred also in GALT of SHIVSF162P4-infected
Figure 1. SHIVSF162P4 loads in plasma (A), CD4+ T cell counts in peripheral blood (B), relative CCL3 (C), CCL4 (D) and CCL5 (E) gene expression
levels in PBMCs at PID 0-180 with SHIVSF162P4. Each point on the graph represents the mean fold change in gene expression relative to pre-infection
level6SE (n=5).
doi:10.1371/journal.pone.0000726.g001
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obtained at PID 0, 14 and 180. At PID 14, CCL3 and CCL4
mRNA levels in colon, jejunum and MLN were lower (p#0.05)
than those at PID 0 (Fig. 2A and B). CCL5 mRNA decreased in
jejunum (p,0.05) but not in colon and MLN. In agreement with
results generated with PBMC, down-regulation of CC-chemokines
occurred also in GALT at PID 14. By PID 180, expression of CC-
chemokines returned to pre-infection levels (CCL4 and CCL5), or
even increased (CCL3).
In situ enumeration of CCL4+ cells in SHIVSF162P4-
infected macaques
To corroborate the mRNA results, and to determine the origin
and number of CC-chemokine-producing cells in SHIVSF162P4-
infected macaques, confocal microscopy and MLN tissues were
used. The CCL4 was selected as the CC-chemokine representa-
tive. The T lymphocytes (CD3+), macrophages (CD68+), and
CCL4+ cells were identified directly in situ by tri-color staining
(Figs. 3 and 4). Higher number of CD3+CCL4+ cells was seen at
PID 0 than at PID 14 (Table 1) while CD3+p28+ cells were seen at
PID 14 but not at PID 0 indicating the rapid spread of virus into
GALTs following mucosal inoculation (Fig. 3). In addition to
CD3+ cells, CD68+ macrophages were also identified as CCL4+
cells (Fig. 4). In agreement with real-time PCR data, the counts of
CD3+CCL4+ and CD68+CCL4+ cells were lower (p,0.05) at
PID 14 than they were at PID 0 (Table 1).
Flow cytometry of CCL4+ cells in peripheral blood of
SHIVSF162P4–infected macaques
Four-color flow cytometry was used to corroborate the gene
expression results. At PID 0, the average proportions of
CD3+CD4+CCL4+ and CD3+CD8+CCL4+ cells over CD3+ T
cells were 5.9% and 6.9%, respectively (Fig. 5B). By PID 14, both
of these proportions decreased (p,0.05 and p,0.01) to 2.2% and
2.3% (Fig. 5B). In order to be able to differentiate between CCL4+
and CCL4- cells, mitogen-stimulated cells were included as
controls (Fig. 5A).
The extent of CC-chemokine gene down-regulation
in blood of SHIV-infected macaques is independent
from the level of CD4+ T cell depletion
We hypothesized that SHIVSF162P4–induced CC-chemokine
down-regulation at acute stage of infection was not proportio-
nately related to peripheral CD4+ T cell depletion as a result of
viral target cell destruction. Therefore, we included in this study
a subset of samples obtained from SHIVKu1-infected macaques (PID
0 and 14). In accord with previous reports [19,20], it was confirmed
thatSHIVKu1infectionwasatPID14associatedwithgreaterplasma
viral loads and more profound loss of peripheral CD4+ T cells than
that caused by SHIVSF162P4 (Fig. 6A and B). Interestingly,
SHIVSF162P4 caused by PID 14 5.9–13.6, 3.5–27.5, and 2.3–5.4-
fold CCL3, CCL4 and CCL5 gene down-regulation respectively,
while only 2.8–6.2, 2.3–7.8, and 1.2–2.2-fold down-regulation was
measured in SHIVKu1-infected macaques (Fig. 6C). These differ-
ences in CC-chemokine down-regulation between SHIVSF162P4-
and SHIVKu1-infected macaques were significant (p,0.05).
DISCUSSION
Main objective of our study was to evaluate the CC-chemokine
gene expression changes in SHIVSF162P4-infected macaques. We
found that at primary/acute stage of infection, CC-chemokine
genes were markedly down-regulated, which coincided with the
peak of viremia. Gene expression results were consistent with
direct measurements of chemokine production–corroborated by
confocal microscopy and flow cytometry. Results generated with
peripheral blood and GALT samples were also consistent. In
Figure 2. Relative CCL3 (A), CCL4 (B) and CCL5 (C) expression levels in GALT tissues at different stages of SHIVSF162P4 infection (n=5). PID 0 was
used as the calibrator (value=1).
doi:10.1371/journal.pone.0000726.g002
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CD8+ intraepithelial lymphocytes (IEL) was observed at the acute
stage of SIV infection [21]. Study by Wen and colleagues [22] also
showed that expression of CCL3, CCL4 and CCL5 decreased in
U937 promonocytes in response to HIV-1 infection. In addition,
several studies reported up-regulation of CC-chemokines during
chronic phase of HIV/SIV infection [14,15,23]. These reports are
not in conflict with our results. Results shown here indicate
however that down-regulation of CCR5 ligands occurred only at
primary (PID 14) but not at chronic stage of SHIVSF164P4 infection
(PID 180). At the chronic stage of SHIVSF164P4 infection,
expression of the CCR5 ligands returned to pre-infection levels
(CCL4 and CCL5), or even increased (CCL3) in all three GALTs.
There are several possible mechanisms involved in decline of
CC-chemokines during primary SHIV infection. Since lympho-
cytes are CC-chemokine producing cells, the depletion of CD4+ T
lymphocytes could be one of the reasons. Based on measurable
and significant CC-chemokine gene down-regulation caused by
SHIVSF162P4 that is known to be less pathogenic in term of its
ability to deplete the peripheral CD4+ T cells than other SHIVs,
SIV or HIV, a subset of samples obtained from SHIVKu1-infected
macaques (PID 0 and 14) was included in this study. It was
hypothesized that SHIVSF162P4–induced CC-chemokine down-
regulation is not directly related to peripheral CD4+ T cell
depletion-as a result of viral target cell destruction. This hypothesis
was conclusively corroborated by measurements of CC-chemokine
gene expression at PID 14 when SHIVSF162P4 was found to cause
significantly greater gene down-regulation than SHIVKu1. Such
result suggests that decline of CC-chemokines cannot be solely
attributed to CD4+ T cell depletion, but it is more complex and
Figure 3. Triple-label confocal microscopy of CCL4+ cells in mesenteric lymph nodes obtained from control (PID 0) and SHIVSF162P4-inoculated
macaques at PID 14. T lymphocytes (CD3+) are red, CCL4+ cells are green, SHIVSF162P4-infected cells (p28+) are blue. Overlap of red and green
fluorescence is seen as yellow, overlap of red and blue as pink. Higher number of CD3+CCL4+ cells was seen at PID 0 than at PID 14 (Table 1) while
CD3+p28+ cells could be seen at PID 14 but not at PID 0 indicating the successful spread of virus into GALTs following mucosal inoculation.
doi:10.1371/journal.pone.0000726.g003
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One of them might be related to SHIV gene products, which
modulate transcriptional levels of host response genes [24]. For
example, HIV accessory gene product Vpr has been reported to
suppress the host CC-chemokine gene expression [25]. Another
candidate pathway is the interaction between the HIV/SIV gp120
and the CCR5 chemokine co-receptors, which trigger not only
viral entry but also other signal transduction cascades that are
impacting host CC-chemokine gene expression [26,27]. Elucidat-
ing such pathways in context of CC-chemokine production can be
subject of future studies.
CCL3, CCL4 and CCL5 function as natural ligands for CCR5,
the major HIV/SIV co-receptor [3]. CC-chemokines are known
to inhibit the CCR5-mediated HIV/SIV infection by blocking the
viral entry into host cells [9,10]. In addition, CC-chemokines play
a role in directing the cell movements necessary for the initiation of
T cell immune responses [1], co-stimulate the T cell proliferation,
and augment the cytolytic capacity of T and NK cells [28,29].
Thus, suppression of CC-chemokines during primary/acute stage
of infection may be an event that facilitates the evasion of HIV/
SIV from the host immune response. It was demonstrated by
several authors that production of CC-chemokines was associated
with vaccine-mediated protection from SIV challenge [13,16,30].
Furthermore, systemic therapy with CC-chemokine homologues
decreased SIVmac251 replication in rhesus monkeys [31]. These
reports are in agreement with our findings by corroborating the
notion that CC-chemokine down-regulation may facilitate virus
spread during acute stage of infection.
It may be unexpected that CCL3, CCL4 and CCL5 are down-
regulated at the acute phase of SHIV infection, since most of the
CC-chemokines belong to proinflammatory chemokines and are
generally considered to be produced only in response to
pathological conditions [32]. However, the constitutive expression
of CCL3, CCL4 and CCL5 was detected in monocytes [33] and
CD8+ intraepithelial lymphocytes [21]. In this study, highly
sensitive real-time PCR was used to measure the expression of the
above CC-chemokines in PBMC and GALTs before and after
SHIVSF162P4 infection, and it was concluded that these chemo-
kines are down-regulated during primary infection.
In summary, we hypothesize that an interventional up-
regulation of CC-chemokines might lead to better outcome of
HIV/SIV primary infection. Evaluation of CC-chemokine
enhancing immunomodulators such as synthetic CpG-oligonu-
cleotides could be explored in future SIV/HIV vaccine studies.
MATERIALS AND METHODS
Animals and virus
Five adult rhesus macaques (Macaca mulatta) of Indian origin were
inoculated with 5,000 TCID50 of CCR5-tropic SHIVSF162P4 via
intrarectal route [19]. SHIVSF162P4 was obtained from the Simian
Retrovirus Core Laboratory at the TNPRC (Tulane National
Primate Research Center). Animals were housed at the TNPRC
under biosafety level 2 conditions in accordance with the
regulations of the American Association for Assessment and
Accreditation of Laboratory Animal Care standards. In addition,
five adult rhesus macaques of Indian origin were inoculated with
CXCR4-tropic SHIVKu1 by using the same route and dose as
described above for SHIVSF162P4. SHIVKu1 was obtained from
NIH (www.aidsreagent.org). Both SHIVs were expanded and
titrated in vitro as described elsewhere [34,35].
Figure 4. Macrophages were also identified as CCL4+ cells.
Macrophages (CD68+) are red, CCL4+ cells are green, overlap of red
and green fluorescence is seen as yellow.
doi:10.1371/journal.pone.0000726.g004
Table 1. Absolute (counts) and relative (%) levels of CCL4+ cells in MLN following SHIVSF162P4 inoculation
..................................................................................................................................................
Sample Date Animal CCL4+CD3+ (count)
a % CCL4+CD3+ over total CD3+ CCL4+CD68+ (count)
a % CCL4+CD68+ over total CD68+
PID 0 Animal 1 12 0.89 7 1.92
Animal 2 7 0.76 8 2.24
Animal 3 8 0.78 6 2.11
Mean6SEM 962 0.8160.04 761 2.0960.09
PID 14 Animal 1 4 0.65 3 0.82
Animal 2 2 0.26 4 1.12
Animal 3 3 0.55 3 1.03
Mean6SEM 361 0.4960.12 361 0.9960.09
aNumber of cells/0.5 mm
2 section.
doi:10.1371/journal.pone.0000726.t001
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From the 5 animals inoculated with SHIVSF162P4, EDTA blood
was collected prior to inoculation (PID 0), and at PID 7, 14, 21,
35, 56 and 180. GALT samples (jejunum, colon and MLN) were
collected via laparotomy biopsies at PID 0, 14 and 180. The
peripheral blood mononuclear cells (PBMC) were isolated from
EDTA blood using the lymphocyte separation medium (Cappel,
Aurora, OH) according to instructions of manufacturer, and
stored in lysis buffer (Qiagen, Valencia, CA) (10610
6 cells/600 ml
of lysis buffer) at 280uC until RNA isolation. The GALT samples
were cut into 20–30 mg pieces, placed in 5 volumes of RNAlater
(Ambion, Austin, TX), incubated at 4uC overnight and stored at
220uC until RNA extraction. From the 5 animals inoculated with
SHIVKu1, samples of EDTA blood were obtained at PID 0 and 14
in order to compare measurements of a) plasma viral load, b)
peripheral CD4+ T cell counts and c) CC-chemokine gene
expression between SHIVSF162P4- and SHIVKu1–infected maca-
ques.
RNA isolation and cDNA preparation
Total RNA was isolated from 20–30 mg of GALT tissue or
10610
6 of PBMC using the RNeasy mini kit (Qiagen, Valencia,
CA). Prior to RNA isolation, tissue was homogenized by 3 pulses
of sonication, each at 60 W for 3 sec. All samples were treated
with RNase-free DNase (Qiagen). cDNA was prepared using the
random hexamer primers (Integrated DNA Technologies, Skokie,
IL) and M-MLV reverse transcriptase (Promega, Madison, WI)
according to instructions of manufacturer.
Figure 5. The proportions of peripheral blood CD3+CD4+CCL4+ and CD3+CD8+CCL4+ T lymphocytes were compared at PID 0 and PID 14 with
SHIVSF162P4 by flow cytometry (A). Gating was performed via CD3+ lymphocyte population. Statistically significant differences between
CD3+CD4+CCL4+ and CD3+CD8+CCL4+ cells over CD3+ lymphocytes at PID 0 vs. PID 14 (n=5) are shown (B).
doi:10.1371/journal.pone.0000726.g005
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real-time PCR
Real-time PCR was carried out using the ABI Prism 7700
Sequence Detection System (Applied Biosystem, Foster City, CA).
Each PCR reaction included 12.5 ml of master mix (DyNAmo HS
SYBR Green qPCR Kit, MJ research, Waltham, MA). It
contained modified DNA polymerase, SYBR Green I, 5 mM
MgCl2, dNTP mix, 0.5 mM of forward and reverse primers,
16ROX reference dye, and 100 ng of the first strand cDNA in
deionized water. After heating each sample to 95uC for 15 min, 40
cycles of 94uC for 10 sec, 55uC for 30 sec, and 72uC for 30 sec
Figure 6. Comparison of SHIVSF162P4 and SHIVKu1 primary infection in peripheral blood. Viral loads in plasma (A), CD4+ T cell counts (B), Fold-
changes of CCL3, CCL4 and CCL5 gene expression levels in SHIVSF162P4- and SHIVKu1–infected macaques at PID 0 vs. PID 14 (C) (n=5 for each group).
Negative sample cut-off for viral load measurements in plasma was ,30 copies/ml e.g. PID 0 value.
doi:10.1371/journal.pone.0000726.g006
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were generated by heating the reaction mixture to 95uC for 15 sec,
then to 60uC for 20 sec, and slowly increasing the temperature to
95uC over a period of 20 min. The fluorescence was measured as
a function of temperature. All samples were run in duplicates and
the PCRs for the housekeeping glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and the target genes (Table 2) were
run in parallel for each sample. PCR reactions were carried out on
a 96-well plate (Applied Biosystems, Foster City, CA) using the
25 ml/reaction volumes. Results were analyzed by SDS 1.9.1
Software (Applied Biosystems). The melting curves were obtained
with ABI Prism 7700 software, version 1.7(http://www.applied-
biosystems.com/support/software/7700pdates.cfm, ABI). The
specificity of real-time PCR was verified by melting curve analysis.
Housekeeping gene GAPDH was used to normalize the RNA in
tested samples. The variation in GAPDH Ct value among the
RNA samples was #3%. 2
2DDCt method [36] was used in
calculating the fold-relationships in gene expression between the
time points. Pre-infection (PID 0) was used as calibrator to
generate the graphs shown in Fig 1 and 2.
Evaluation of viral loads by real-time PCR
Quantitative assessment of viral RNA load in plasma samples
obtained from peripheral blood of SHIV-inoculated macaques was
determined by real-time reverse transcriptase PCR as described in
detail elsewhere [37]. The virus used in this study was accurately
and equivalently quantified in this assay. The values were
expressed as viral RNA copies per ml of plasma.
Enumeration of CCL4-producing cells in MLN by
confocal microscopy
MLN biopsies obtained from 3 animals prior to infection (PID 0)
and at PID 14 were cryosectioned to 10–16 mm and subjected to
immunofluorescence staining as previously described [38]. Briefly,
the tissues were blocked with 10% donkey serum (Sigma, St. Louis,
MO) in PBS containing 0.2% fish skin gelatin (Sigma, St. Louis,
MO). The sections were subsequently stained with primary
antibodies to detect CCL4+ cells, SHIV-infected cells, T cells
and macrophages (anti-CCL4, SIV gag p28, CD3, and CD68
antibodies were purchased from R&D Systems, Microbix, Dako
and BD Pharmingen, respectively). Negative-control samples were
stained with matched isotype control antibodies and no positive
cells were identified (not shown). Primary staining was followed by
incubation with secondary antibodies conjugated to fluoro-
chromes. Images were captured by a Leica TCS SP2 laser-
scanning microscope (Leica Microsystems, Exton, PA) and viewed
using the Leica imaging software [38].
Flow cytometry analysis of CCL4 expression in
CD3+CD4+/CD8+ T cells
Presence of intracellular CCL4 in PBMC was evaluated by four-
color flow cytometry. The following anti-human monoclonal
antibodies that cross-react with rhesus macaques were used:
Phycoerythrin (PE)-conjugated anti-MIP-1b/CCL4 (clone D21-
1351), Fluorescein isothiocyanate (FITC)-conjugated anti-CD3
(clone SP34), Peridinin Chlorophyll (PerCP)-conjugated anti-CD8
(clone SK1), and Allophycocyanin (APC)-conjugated anti-CD4
(clone SK3). All antibodies were purchased from BD-Pharmingen
(Pharmingen, San Diego, CA). PBMCs (5610
5 per sample) were
first incubated with fluorochrome-conjugated antibodies to CD3,
CD4 and CD8 at 4uC, in dark, for 30 min. The cells were then
washed with PBS containing 0.2% fetal bovine serum (FBS,
Invitrogen, Chicago, IL), and permeabilized with 16 fixation/
permeabilization solution (BD Biosciences) for 10 min at room
temperature. Following two washes with PBS containing 0.2%
FBS, the cells were incubated with anti-CCL4 for 30 min at 4uC.
After washing, cells were resuspended in 2% paraformaldehyde/
PBS. Positive control PBMCs were stimulated with 100 ng/ml of
phorbol myristate acetate (PMA, Sigma) and 1 mg/ml of
ionomycin (Sigma) for 6 h at 37uC, 5% CO2. Brefeldin-A
(10 mg/ml, Sigma) was added for final 5 h. Mitogen-stimulated
control PBMCs were stained and processed as described above for
unstimulated samples. Negative-control samples were stained with
matched isotype control antibodies. Stained cells were kept
protected from light at 4uC and acquisition was completed within
48 h. Data acquisition was performed using the FACS-Aria Flow
Cytometer (BD Biosciences), and collected data were analyzed by
Cell Quest software (Becton Dickinson).
Statistical analysis
CCL3, CCL4 and CCL5 mRNA levels, CCL4+ cell numbers in
MLN and percentages of CCL4+ cells in peripheral blood CD4+
and CD8+ T cell populations were compared between selected
time points of SHIVSF162P4-infected macaques by Student’s t test
and a p,0.05 was considered statistically significant. In addition,
the extent of CC-chemokine down-regulation in peripheral blood
of SHIVSF162P4- and SHIVKu1-infected macaques was compared
at PID 14 by Student’s t test (p,0.05).
Table 2. Rhesus macaque-specific primers for real-time PCR
..................................................................................................................................................
Gene GenBank # Sequences (59-39) Start-End Position Amplicon Length (bp)
CCL3 AF449266 F: CAACATTTGCTGCTGACACC 68–87 103
R: CACTGGCTGTTGGTCTCAAA 151–170
CCL4 AF449267 F: CCAGACCAAAAGAGGCAAGC 195–214 76
R: TTCCAGGTCATTAACATACTCC 249–270
CCL5 AF449268 F: TACACCAGTGGCAAGTGCTC 154–173 100
R: TGTACTCCCGAACCCATTTC 234–253
GAPDH CO774505 F: GGGAGCCAAAAGGGTCATCA 378–397 91
R: GAGGCTGTTGTCATACTTCTC 448–468
doi:10.1371/journal.pone.0000726.t002
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